The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | The potential of adding anti-CD20 antibodies to acalabrutinib and venetoclax in CLL
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, discusses the potential value of adding anti-CD20 antibodies to the combination of venetoclax and acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL). He mentions that this may be valuable in mantle cell lymphoma (MCL); however, CD20 expression is low in CLL, so this may not be beneficial. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
